Response of Severe Lupus Miliaris Disseminatus Faciei to Treatment With Ruxolitinib Cream
JAMA Dermatology · 2023
DOI: 10.1001/jamadermatol.2023.0528 ↗Kurz gefasst
Fachartikel in der Zeitschrift JAMA Dermatology, 2023. Verfasst von Natalie C Gorham und 2 weiteren Autor:innen. Beteiligte Einrichtung: Maryland Dermatology, Laser, Skin, and Vein Institute, Hunt Valley, Maryland. Hauptthemen laut MEDLINE: Rosacea. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 6 Literaturangaben.
Abstract (Originalsprache)
This case report describes a 46-year-old woman who presented with numerous monomorphic, mildly erythematous, and skin-colored smooth indurated papules that coalesced into plaques that involved the upper and lower eyelids, forehead, medial cheeks, cutaneous lips, and chin.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Maryland Dermatology, Laser, Skin, and Vein Institute, Hunt Valley, Maryland.
- Department of Pathology, University of Maryland Medical Center, Baltimore, Maryland.
Zitieren
APA
Gorham, N. C., Jacobs, J., & Wu, S. Z. (2023). Response of Severe Lupus Miliaris Disseminatus Faciei to Treatment With Ruxolitinib Cream. JAMA Dermatology. https://doi.org/10.1001/jamadermatol.2023.0528
Vancouver
Gorham NC, Jacobs J, Wu SZ. Response of Severe Lupus Miliaris Disseminatus Faciei to Treatment With Ruxolitinib Cream. JAMA Dermatology. 2023. doi:10.1001/jamadermatol.2023.0528
BibTeX
@article{Gorham2023,
author = {Gorham, Natalie C and Jacobs, Jonathan and Wu, Sean Z},
title = {Response of Severe Lupus Miliaris Disseminatus Faciei to Treatment With Ruxolitinib Cream},
journal = {JAMA Dermatology},
year = {2023},
doi = {10.1001/jamadermatol.2023.0528}
}
EUVIMED